SCHEMBL2833795

SCHEMBL2833795

CC(C)Oc1ccc(C(=O)C(NC(=O)OC(C)(C)C)c2ccc(Cl)c(Cl)c2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 5/20 0.51
TRPA1 O75762 1/20 0.49
NR3C1 P04150 2/20 0.37
AAK1 Q2M2I8 1/20 0.37
ACACB O00763 3/20 0.35
HRH3 Q9Y5N1 1/20 0.35
S1PR1 P21453 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
S1PR2 O95136 1/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ABCB1 P08183 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836601 0.85 S1PR3 (0.51) S1PR3TRPA1AAK1S1PR1S1PR2
SCHEMBL2836776 0.82 S1PR3 (0.46) S1PR3TRPA1AAK1ACACB
SCHEMBL2833723 0.82 S1PR3 (0.50) S1PR3TRPA1S1PR1S1PR2ABCB1
SCHEMBL2833250 0.81 S1PR3 (0.44) S1PR3TRPA1ACACB
SCHEMBL2832219 0.79 S1PR3 (0.47) S1PR3TRPA1AAK1S1PR1S1PR2
SCHEMBL2838232 0.79 S1PR3 (0.46) S1PR3TRPA1AAK1
SCHEMBL2833345 0.77 RXRA (0.47) S1PR3CTSSCTSK
SCHEMBL2836778 0.77 CHRNA1 (0.42) S1PR3TRPA1ACACBCTSSCTSK
SCHEMBL2833197 0.77 S1PR3 (0.46) S1PR3TRPA1
SCHEMBL2834227 0.77 S1PR3 (0.49) S1PR3TRPA1S1PR2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885TRPA1 3113/4885NR3C1 1183/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885TRPA1 3113/4885NR3C1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.